AFFILIATIONS
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 Fred Hutch Center For Community Health Promotion, Sunnyside, Washington, United States
6 The Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan
7 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
10 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States
11 University of Michigan, Ann Arbor, Michigan, United States
12 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
13 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
14 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
ackground:
The utilization of post-transplant cyclophosphamide (PTCy) has expanded access to allogeneic hematopoietic cell transplantation (allo-HCT) across HLA barriers, demonstrating efficacy in mitigating graft-versus-host disease (GVHD) in haploidentical and mismatched unrelated donor (MMUD) settings. However, within a homogeneous platform of HLA-mismatched recipients receiving PTCy, the optimal conditioning intensity remains debated. We evaluated the impact of conditioning intensity on clinical outcomes in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing HLA-mismatched allo-HCT with PTCy prophylaxis.
Methods:
We conducted a retrospective registry analysis of adult patients with AML or MDS who underwent their first allo-HCT between 2017 and 2021 using an HLA-mismatched donor (haploidentical related or single-locus MMUD) and uniform PTCy-based GVHD prophylaxis, rusing publicly available P-6144 dataset from Center for International Blood and Marrow Transplant Research (CIBMTR). Patients were stratified by center-reported conditioning intensity into myeloablative conditioning (MAC) or reduced-intensity/non-myeloablative conditioning (RIC/NST). Primary endpoints were overall survival (OS), progression-free survival (PFS), and GVHD-free relapse-free survival (GRFS), estimated by the Kaplan–Meier method. Secondary endpoints included cumulative incidence of relapse (CIR) and non-relapse mortality (NRM), analyzed under a competing-risks framework using Fine–Gray subdistribution hazards models. Multivariable Cox models adjusted for recipient age, HCT-Comorbidity Index (HCT-CI), Karnofsky performance status (KPS), refined Disease Risk Index (DRI), primary diagnosis, and graft source. A two-sided p-value <0.05 was considered statistically significant.
Results:
A total of 4,868 patients were included (AML n=3,506 [72.0%]; MDS n=1,362 [28.0%]), of whom 1,924 (39.5%) received MAC and 2,944 (60.5%) received RIC/NST. Patients in the RIC/NST group were significantly older (median age 63 vs 46 years, p<0.001), more often had KPS <90 (48.6% vs 34.7%, p<0.001), higher comorbidity burden (HCT-CI ≥3: 29.5% vs 22.8%, p<0.001), and MDS diagnosis (33.4% vs 19.6%, p<0.001). Female sex was similar (41.5% vs 42.7%, p=0.453). Peripheral blood grafts were used in 75.8% of MAC and 78.3% of RIC/NST recipients (p=0.049). Haploidentical donors accounted for the majority in both arms. In unadjusted analyses, MAC was associated with superior 2-year OS (54.1% vs 44.3%, p<0.001), PFS (47.3% vs 36.1%, p<0.001), and GRFS (31.4% vs 22.1%, p<0.001). Two-year CIR was lower with MAC (32.1% vs 44.2%, p<0.001), while 2-year NRM was comparable (20.6% vs 19.7%, p=0.482). After multivariable adjustment, RIC/NST remained associated with increased risk of death (aHR 1.28, 95% CI 1.14–1.43, p<0.001), inferior PFS (aHR 1.34, 95% CI 1.20–1.49, p<0.001), and inferior GRFS (aHR 1.21, 95% CI 1.10–1.33, p<0.001). Competing-risks modeling confirmed that the survival benefit of MAC was driven by superior disease control: the hazard of relapse was significantly higher with RIC/NST (aHR 1.46, 95% CI 1.31–1.62, p<0.001). There was no significant difference in adjusted NRM (aHR 0.96, 95% CI 0.82–1.11, p=0.580).
Conclusions:
In AML and MDS patients undergoing HLA-mismatched or haploidentical allo-HCT with uniform PTCy prophylaxis, myeloablative conditioning provided superior survival and disease-free outcomes compared with reduced-intensity protocols. This benefit was mediated by a substantial reduction in relapse risk without any excess non-relapse mortality. These findings support preferential use of MAC over RIC/NST, when clinically feasible, for eligible adult patients in the PTCy platform.